Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.20.4
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating expenses:    
Research and development $ 8,310 $ 7,900
General and administrative 4,389 3,693
Total operating expenses 12,699 11,593
Operating loss (12,699) (11,593)
Other (income) expense:    
Governmental assistance - research incentives (205) (856)
Other income, net (229) (119)
Total other income, net (434) (975)
Loss before income tax expense (12,265) (10,618)
Income tax expense 27 31
Net loss (12,292) (10,649)
Other comprehensive income (loss)    
Unrealized (gain) loss on marketable securities 4 (2)
Net loss and comprehensive loss $ (12,296) $ (10,647)
Basic and diluted net loss per share (in dollars per share) $ (0.78) $ (0.89)
Weighted average shares outstanding – basic and diluted (in shares) 15,680,320 11,987,696